Case report does not distinguish HHV-6A from HHV-6B nor possible role of virus in other organ pathology.
Differentially expressed HHV-6A/B and HHV-7 genes may have prognostic value in gliomas
Unclear if viral gene expression signature confers prognostic information that is independent of host cell gene expression signatures.
Herpesvirus reactivation during alloHSCT associated with greatly increased mortality and expense
Data from 13,363 transplant patients underline the importance of preventing, diagnosing and treating viral reactivation.
Another report links HHV-6B nucleic acid and antigen to mesial temporal lobe epilepsy
Viral DNA and antigen found at higher levels in MTLE than in control brains.
HHV-6 DNA often found in cerebrospinal fluid in samples tested for meningitis
Those with viral infections showed no difference in white or red blood cell counts or the protein and glucose levels.
Artesunate compares favorably to herpesvirus antivirals in suppressing HHV-6 and HHV-7
Non-randomized study finds somewhat more potent reduction of virus in leucocytes over several months of treatment.
Virus specific T cell infusions show promise for preventing HHV-6B reactivation in transplant patients
Review highlights the importance of cell mediated immunity and the limitations of antivirals, vaccines and immunoglobulin therapy for HHV-6, VZV and HSV.
HHV-6 found in postmortem study of myalgic encephalomyelitis/chronic fatigue syndrome
Because of small number of ME/CFS subjects, the study is provocative rather than conclusive.
Increased HHV-6B viral load and levels of autonomic autoantibodies in ME/CFS
Biomarkers distinguish cases from healthy controls, but don’t all correlate with disease severity.
Reference values established for virus specific T-cells in healthy adults
These values may help determine the type of treatment transplant patients should receive: antiviral or adoptive T-cell therapy or a reduction in immunosuppression.
HHV-6 encephalitis following CAR-T cell therapy
A growing number of case reports reveal reactivation similar to that seen after hematopoietic stem cell therapy. Could CAR-T cells be a source of lytic HHV-6?
The dUTPases of HHV-6A and EBV may encourage autoimmunity in ME/CFS
Viral dUTPases are strong inducers of activin A and enhance T follicular helper-cell differentiation.
Elevated HHV-6 and EBV dUTPase antibody levels found in older populations
It remains unclear if there are lower levels of these antibodies in younger age groups.
Reactivation of latent herpesviruses and HERVS after mild COVID-19
Findings are accentuated in people with myalgic encephalomyelitis/chronic fatigue syndrome.
Differences in the cytopathic effect of HHV-6A and HHV-6B infection of neurons and glia
In vitro studies confirm that the two viruses infect different cell types, and generate different cytopathic effects, cytokine and growth factor responses.